Cambridge, Massachusetts, U.S., and Shenzhen, China, October 2, 2026
XtalPi has announced that its proprietary hair loss drug program has advanced into IND-enabling studies, marking an important step in the company’s efforts to develop a potential new treatment for androgenetic alopecia, commonly known as pattern hair loss. The program is now undergoing pharmacology, safety, and chemistry, manufacturing and controls (CMC) studies intended to support a future Investigational New Drug (IND) application. XtalPi, an AI- and robotics-driven drug and materials discovery company, is applying its technology platform to identify and optimize a candidate designed to address biological mechanisms involved in hair follicle regeneration.
XtalPi Targets Hair Follicle Stem Cell Activation
The company’s proprietary program focuses on the lactate–autophagy pathway, which is being investigated for its potential role in reactivating quiescent hair follicle stem cells. Autophagy is a cellular recycling process that helps maintain cellular function by removing and recycling damaged components. According to XtalPi, preliminary research indicates that its candidate may restore cellular autophagy and increase lactate production, potentially helping activate dormant stem cells and support renewed hair growth. These findings are being evaluated as the program progresses through additional preclinical development and IND-enabling work. Androgenetic alopecia affects both men and women and commonly requires long-term management. Existing treatments include topical minoxidil and oral finasteride, but treatment responses can vary and continued use is generally required to maintain benefits. XtalPi is therefore investigating a differentiated approach focused on biological mechanisms associated with hair follicle stem-cell activation rather than relying solely on established treatment pathways. The company is evaluating factors including mechanism of action, dose-response relationships, pharmacokinetics, safety margins, and suitability for long-term treatment as it works toward developing a potential prescription medicine.
Preclinical Data Support Further Drug Development
XtalPi reported encouraging findings from a DHT-induced mouse model of androgenetic alopecia. In the study, a candidate achieved a hair-growth score comparable to that observed with 5% topical minoxidil, while being evaluated at one-hundredth of the comparator’s concentration. Additional preclinical observations indicated potential activity in reducing local follicular inflammation, supporting further investigation of low-concentration topical formulations and their effects on the follicular environment. The company emphasized that these findings remain preclinical and that additional studies are required to establish the candidate’s safety, efficacy, and suitability for human clinical development. The drug discovery process combines AI-guided molecular design, physics-based free-energy perturbation (FEP) calculations, robotic synthesis, and automated testing. XtalPi says this integrated approach has helped researchers optimize target potency and selectivity while also evaluating skin penetration, safety, and developability for topical delivery. The company is building on previous work in scalp care, including two AI-developed proprietary ingredients, Remeanagen™ and AquaKine™, which have received International Nomenclature of Cosmetic Ingredients names.
Advertisement
The move into IND-enabling studies represents a meaningful development milestone for XtalPi’s hair loss drug program. The ongoing pharmacology, safety, and CMC work will be important in determining whether the candidate can progress toward an IND submission and eventual human clinical trials. The program also demonstrates how artificial intelligence and robotics are increasingly being integrated into pharmaceutical drug discovery and development, including therapeutic areas such as dermatology and hair health.
Source: XtalPi press release
